Law Seminars International (LSI) will be offering a one-hour telebriefing entitled "FTC v. Actavis: Practical Implications of the Landmark Supreme Court Decision" on July 16, 2013 from 3:00 to 4:00 pm (Eastern). Jarod M. Bona of DLA Piper will moderate a panel that includes Markus H. Meier, Assistant Director, Health Care Division, Bureau of Competition, Federal Trade Commission; and Rohit K. Singla of Munger Tolles & Olson LLP. The panel will discuss the practical implications of this landmark case and related antitrust issues involving pharmaceutical patents. Among the topics to be covered are:
Practical tips for drafting patent-settlement agreements going forward
• FTC perspective on reverse-payment settlements and the underlying litigation of the decision
• Possible implications beyond pharmaceutical-patent settlements
• Likely impacts on future litigation and patent settlements
A Q&A will follow the presentation and last for up to 30 minutes.
The registration fee is $150 per caller and $100 for each additional person on the same line who desires continuing education credit. Those interested in registering for the telebriefing, can do so here.